Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $1.15 per share a year ago.
Viridian Therapeutics, Inc. (VRDN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Viridian Therapeutics (VRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1 per share in line with the Zacks Consensus Estimate. This compares to a loss of $1.02 per share a year ago.
Viridian Therapeutics: The Song Remains The Same
Viridian Therapeutics is targeting thyroid eye disease with late-stage assets, and shares have dropped significantly over the past six months, despite no major negative news. Analyst sentiment remains bullish, with multiple Buy ratings and price targets far above current levels. The company has a couple of milestones upcoming in 2025 and more pivotal once scheduled in 2026 including a likely FDA approval.
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $0.79 per share a year ago.
Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window
Viridian Therapeutics' VRDN-001 shows promising data in treating Thyroid Eye Disease (TED), with strong proptosis and diplopia resolution rates, rivaling Amgen's Tepezza. Positive results from Thrive and Thrive-2 trials bolster confidence, with VRDN-001 demonstrating rapid response and consistent efficacy in both active and chronic TED. Financially stable with a cash runway into 2027, Viridian is well-positioned for FDA approval, expected to be a significant catalyst for the stock.
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to loss of $1.35 per share a year ago.
Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade)
Company reported positive phase 3 THRIVE-2 study results using veligrotug in treating chronic thyroid eye disease patients, positioning it to file a BLA in the 2nd half 2025. The company is developing VRDN-003, an improved subcutaneous version of veligrotug for TED patients, with phase 3 REVEAL-1 and REVEAL-2 topline data expected in early 2026. Promising pipeline candidates include FcRn inhibitors VRDN-006 and bispecific VRDN-008, targeting IgG-mediated autoimmune disorders with potentially superior efficacy.
Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation
Viridian's veligrotug delivered positive data from two phase 3 trials in active and chronic TED patients. The results from the THRIVE-2 trial in chronic TED patients show hints of differentiation to Tepezza with statistically significant effects on diplopia response and diplopia resolution. Veligrotug's results also provide clinical de-risking for next-generation, subcutaneously administered candidate VRDN-003, which I expect to be the key long-term growth driver for the TED franchise.
Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)
Viridian Therapeutics, Inc.'s stock surged over 20% after key trial results came out before the bell on Monday. The study results triggered a rash of buy reissuances from analyst firms and improved the chances of FDA approval for the company's lead candidate in 2026. Even after the rally in VRDN stock on Monday, the stock remains undervalued given its potential market. The company also has a large cash balance.
Viridian Therapeutics' eye disorder drug meets late-stage study goal
Viridian Therapeutics said on Monday its experimental drug to treat an immune system disorder, chronic thyroid eye disease, met the main goal of a late-stage study.
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.15 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.09 per share a year ago.
